Page 3«..2345..1020..»

Precision NanoSystems to host nanomedicines symposium – European Pharmaceutical Review

§ July 11th, 2017 § Filed under Nano Medicine Comments Off on Precision NanoSystems to host nanomedicines symposium – European Pharmaceutical Review

news

Join Precision NanoSystems for its second annual nanomedicines symposium

Join Precision NanoSystems for its second annual nanomedicines symposium, entitled Nanomedicines: enabling new therapeutic modalities, on the 15of July in Boston, MA. Following the success of last years inaugural event, the symposium will bring together distinguished researchers and drug developers from across the nanomedicines industry, and will precede the Controlled Release Societys Annual Meeting and Exposition from the 16to 18of July.

The symposium schedule has been designed to provide an overview of the latest developments in nanomedicine research, including strategies for overcoming in vitro and in vivo barriers to effective and targeted drug delivery. It will cover a diverse range of applications, with the keynote address To target or not to target: lessons from RNAi-based targeted lipid nanoparticles being provided by Professor Dan Peer from the Department of Cell Research and Immunology at Tel Aviv University. Other topics covered during the symposium will explore cutting-edge research in the fields of gene therapy, genetic vaccines and small molecule delivery. This will include industry talks from GSK, CureVac and Genentech, as well as presentations from the Beth Israel Deaconess Medical Centre, the University of British Columbia and Houston Methodist/Weill Cornell Medical College.

The symposium will also give attendees a chance to explore the latest enabling technologies in the nanomedicines sector with presentations from Precision NanoSystems and event sponsors Spectradyne, SpectrumLabs, Malvern Instruments and Sigma-Aldrich as well as providing networking opportunities throughout the day.

For those unable to attend the event in person, you can still enjoy a virtual front row seat via a free livestream. Register now to join the event online.

Go here to see the original:
Precision NanoSystems to host nanomedicines symposium – European Pharmaceutical Review

Read the Rest...

Koch Institute’s Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer – AZoNano

§ July 10th, 2017 § Filed under Nano Medicine Comments Off on Koch Institute’s Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer – AZoNano

Written by AZoNanoJul 10 2017

The Koch Institute for Integrative Cancer Research at MIT will soon be reaching the first anniversary of the launch of the Marble Center for Cancer Nanomedicine, founded through a generous gift from Kathy and Curt Marble 63.

The Marble Center for Cancer Nanomedicines faculty is made up of Koch Institute members who are committed to fighting cancer with nanomedicine through research, education, and collaboration. Top row (l-r) Sangeeta Bhatia, director; Daniel Anderson; and Angela Belcher. Bottom row: Paula Hammond; Darrell Irvine; and Robert Langer. (Photo: Koch Institute Marble Center for Cancer Nanomedicine)

Bringing together leading Koch Institute faculty members and their teams, the Marble Center for Cancer Nanomedicine focuses on huge challenges in cancer detection, treatment and monitoring that can profit from the latest physics and biology of the nanoscale.

These challenges include spotting cancer earlier than present techniques allow, harnessing the immune system to combat cancer even as it progresses, using therapeutic insights from cancer biology to design therapies for formerly undruggable targets, integrating current drugs for synergistic action, and developing tools for more accurate diagnosis and improved surgical intervention.

Koch Institute member Sangeeta N. Bhatia, the John J. and Dorothy Wilson, Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, serves as the Inaugural Director of the center.

A major goal for research at the Marble Center is to leverage the collaborative culture at the Koch Institute to use nanotechnology to improve cancer diagnosis and care in patients around the world.

Sangeeta N. Bhatia, Koch Institute Member

Transforming nanomedicine

The Marble Center joins MITs larger efforts at the forefront of discovery and advancement to solve the critical global challenge that is cancer. The concept of convergence the combination of the life and physical sciences with engineering is a trademark of MIT, the founding principle of the Koch Institute, and at the heart of the Marble Centers mission.

The center galvanizes the MIT cancer research community in efforts to use nanomedicine as a translational platform for cancer care. Its transformative by applying these emerging technologies to push the boundaries of cancer detection, treatment, and monitoring and translational by promoting their development and application in the clinic.

Tyler Jacks, Director of the Koch Institute and a David H. Koch Professor of Biology

The centers faculty six renowned MIT Professors and Koch Institute Members are committed to combating cancer with nanomedicine through research, education and partnership. They are, Sangeeta Bhatia (director), the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science; Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology in the Department of Chemical Engineering and the Institute for Medical Engineering and Science; Angela M. Belcher, the James Mason Crafts Professor in the departments of Biological Engineering and Materials Science and Engineering; Paula T. Hammond, the David H. Koch Professor of Engineering and head of the Department of Chemical Engineering; Darrell J. Irvine, Professor in the departments of Biological Engineering and Materials Science and Engineering; and Robert S. Langer, the David H. Koch Institute Professor.

Extending their partnership within the walls of the Institute, members of the Marble Center profit greatly from the support of the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institutes Robert A. Swanson (1969) Biotechnology Center. The Peterson Facilitys array of technological resources and know-how is unparalleled in the United States, and gives members of the center and of the Koch Institute, a distinctive advantage in the development and application of materials and technologies at the nanoscale.

Looking ahead

The Marble Center made the most of its first year, and has provided backing for advanced research projects including theranostic nanoparticles that can both detect and treat cancers, real-time imaging of interactions between cancer and immune cells to properly understand reaction to cancer immunotherapies, and delivery technologies for a number of powerful RNA-based therapeutics capable of engaging specific cancer targets with precision.

As part of its efforts to help adopt a multifaceted science and engineering research force, the center has offered fellowship support for trainees as well as valuable opportunities for scientific exchange, mentorship and professional development.

Promoting wider engagement, the Marble Center serves as a bridge to a broad network of nanomedicine resources, linking its members to MIT.nano, other Nanotechnology Researchers, and Clinical Partners across Boston and beyond. The center has also set up a scientific advisory board, whose members come from leading clinical and academic centers around the country, and will assist in shaping the centers future programs and continued development.

As the Marble Center enters another year of partnerships and innovation, there is a new landmark in sight for 2018. Nanomedicine has been chosen as the main theme for the Koch Institutes 17th Annual Cancer Research Symposium. The event is scheduled for June 15th, 2018, and will bring together national domain experts, providing a perfect forum for Marble Center members to share the discoveries and progresses made during its sophomore year.

Having next years KI Annual Symposium dedicated to nanomedicine will be a wonderful way to further expose the cancer research community to the power of doing science at the nanoscale. The interdisciplinary approach has the power to accelerate new ideas at this exciting interface of nanotechnology and medicine.

Sangeeta N. Bhatia, Koch Institute Member

More:
Koch Institute’s Marble Center for Cancer Nanomedicine Brings Together Renowned Faculty to Combat Cancer – AZoNano

Read the Rest...

Converging on cancer at the nanoscale – The MIT Tech

§ July 8th, 2017 § Filed under Nano Medicine Comments Off on Converging on cancer at the nanoscale – The MIT Tech

This summer, the Koch Institute for Integrative Cancer Research at MIT marks the first anniversary of the launch of the Marble Center for Cancer Nanomedicine, established through a generous gift from Kathy and Curt Marble 63.

Bringing together leading Koch Institute faculty members and their teams, the Marble Center for Cancer Nanomedicine focuses on grand challenges in cancer detection, treatment, and monitoring that can benefit from the emerging biology and physics of the nanoscale.

These challenges include detecting cancer earlier than existing methods allow, harnessing the immune system to fight cancer even as it evolves, using therapeutic insights from cancer biology to design therapies for previously undruggable targets, combining existing drugs for synergistic action, and creating tools for more accurate diagnosis and better surgical intervention.

Koch Institute member Sangeeta N. Bhatia, the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science, serves as the inaugural director for the center.

A major goal for research at the Marble Center is to leverage the collaborative culture at the Koch Institute to use nanotechnology to improve cancer diagnosis and care in patients around the world, Bhatia says.

Transforming nanomedicine

The Marble Center joins MITs broader efforts at the forefront of discovery and innovation to solve the urgent global challenge that is cancer. The concept of convergence the blending of the life and physical sciences with engineering is a hallmark of MIT, the founding principle of the Koch Institute, and at the heart of the Marble Centers mission.

The center galvanizes the MIT cancer research community in efforts to use nanomedicine as a translational platform for cancer care, says Tyler Jacks, director of the Koch Institute and a David H. Koch Professor of Biology. Its transformative by applying these emerging technologies to push the boundaries of cancer detection, treatment, and monitoring and translational by promoting their development and application in the clinic.

The centers faculty six prominent MIT professors and Koch Institute members are committed to fighting cancer with nanomedicine through research, education, and collaboration. They are:

Sangeeta Bhatia (director), the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science;

Daniel G. Anderson, the Samuel A. Goldblith Professor of Applied Biology in the Department of Chemical Engineering and the Institute for Medical Engineering and Science;

Angela M. Belcher, the James Mason Crafts Professor in the departments of Biological Engineering and Materials Science and Engineering;

Paula T. Hammond, the David H. Koch Professor of Engineering and head of the Department of Chemical Engineering;

Darrell J. Irvine, professor in the departments of Biological Engineering and Materials Science and Engineering; and

Robert S. Langer, the David H. Koch Institute Professor.

Extending their collaboration within the walls of the Institute, Marble Center members benefit greatly from the support of the Peterson (1957) Nanotechnology Materials Core Facility in the Koch Institutes Robert A. Swanson (1969) Biotechnology Center. The Peterson Facilitys array of technological resources and expertise is unmatched in the United States, and gives members of the center, and of the Koch Institute, a distinct advantage in the development and application of nanoscale materials and technologies.

Looking ahead

The Marble Center has wasted no time getting up to speed in its first year, and has provided support for innovative research projects including theranostic nanoparticles that can both detect and treat cancers, real-time imaging of interactions between cancer and immune cells to better understand response to cancer immunotherapies, and delivery technologies for several powerful RNA-based therapeutics able to engage specific cancer targets with precision.

As part of its efforts to help foster a multifaceted science and engineering research force, the center has provided fellowship support for trainees as well as valuable opportunities for mentorship, scientific exchange, and professional development.

Promotingbroader engagement, the Marble Center serves as a bridge to a wide network of nanomedicine resources, connecting its members to MIT.nano, other nanotechnology researchers, and clinical collaborators across Boston and beyond. The center has also convened a scientific advisory board, whose members hail from leading academic and clinical centers around the country, and will help shape the centers future programs and continued expansion.

As the Marble Center begins another year of collaborations and innovation, there is a new milestone in sight for 2018.Nanomedicine has been selected as the central theme for the Koch Institutes 17th Annual Cancer Research Symposium. Scheduled for June 15, 2018, the event will bring together national leaders in the field, providing an ideal forum for Marble Center members to share the discoveries and advancements made during its sophomore year.

Having next years KI Annual Symposium dedicated to nanomedicine will be a wonderful way to further expose the cancer research community to the power of doing science at the nanoscale, Bhatia says. The interdisciplinary approach has the power to accelerate new ideas at this exciting interface of nanotechnology and medicine.

To learn more about the people and projects of the Koch Institute Marble Center for Cancer Nanomedicine, visit nanomedicine.mit.edu.

Excerpt from:
Converging on cancer at the nanoscale – The MIT Tech

Read the Rest...

Semiconductor-laced bunny eyedrops appear to nuke infections – The Register

§ July 8th, 2017 § Filed under Nano Medicine Comments Off on Semiconductor-laced bunny eyedrops appear to nuke infections – The Register

Don’t worry, little guy. They’re really, really small!

In early lab experiments on rabbits, eyedrops laced with nanoparticles appear to combat bacterial keratitis, a serious infection of the cornea which can, in severe cases, cause blindness.

Researchers hope that these nanoparticles could someday offer a non-toxic alternative to antibiotics, which have the undesirable side effect of creating resistant bacteria.

A common treatment option is steroids, but they can cause scarring. Boffins have found that some nanomaterials, such as copper oxide and silicon, appear to damage bacterial cells. Lately, some groups have realised that carbon quantum dots really tiny semiconductors seem to offer similar benefits with low toxicity, the ability to disperse in water easily, and a relatively simple fabrication process.

“We think it should be safe,” Han-Jia Lin, a biochemist at National Taiwan Ocean University in Keelung, told The Register. He and his team had previously studied quantum dots for wound healing in rats.

In the new study, Lin and his team created carbon quantum dots approximately six nanometers in diameter by heating spermidine at around 200oC for about three hours and placing the resultant dots in liquid. The ratio was about 0.4 per cent quantum dot to liquid.

The team infected rabbits with bacterial keratitis. Some received 4 per cent SMX antibiotics, some the quantum-filled eye drops, and others no treatment for control. The researchers found that the quantum dot eyedrop solution showed therapeutic effects right away, even after the first day. The dots were small enough to sneak into the cornea and destroy the bacterial cells.

This had something to do with the quantum dots’ compatibility with the cells as well as how they destabilised the cell membranes. The researchers don’t know exactly why they work.

By two weeks, the rabbits’ eyes were mostly better the quantum dot eyedrop worked about as well as antibiotics. Lin says the treated rabbits showed no side effects from treatment.

A paper describing the research appeared this week in ACS Nano.

It’s a “conceptually and technically quite elegant study with remarkable results” but “still with a couple of open questions and obvious risks before this could lead to any product that could help patients,” Claus-Michael Lehr, a nanomedicine researcher at Saarland University in Saarbrcken, Germany, told The Reg.

First, he said the reasons why the nanomedicine has such strong bactericidal effects is “not easily explained”. Second, the effect of opening tight junction tissue barriers (a potential risk in itself) needs to be shown to be reversible. Third, what chemical products are formed by the quantum dots are they toxic or carcinogenic?

Finally, he said it was wasn’t clear how quantum dots that penetrate tissue would behave in the long term. “These structures are probably not biodegradable,” he said, “and if they were, what metabolites are being formed?”

Lin says the next steps are to test the long-term effects of the quantum dots, but the the team is trying to be careful in their research to try to limit how they accumulate in bodies. Here, for example, they tested them on the eye.

Because the carbon quantum dots work on such a sensitive part of the body such as the eye without apparently harming cells, “This has potential,” Lin said.

See original here:
Semiconductor-laced bunny eyedrops appear to nuke infections – The Register

Read the Rest...

Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

§ July 6th, 2017 § Filed under Nano Medicine Comments Off on Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

Nanotechnology is one of the most promising technologies in 21st century. Nanotechnology is a term used when technological developments occur at 0.1 to 100 nm scale. Nano medicine is a branch of nanotechnology which involves medicine development at molecular scale for diagnosis, prevention, treatment of diseases and even regeneration of tissues and organs. Thus it helps to preserve and improve human health. Nanomedicine offers an impressive solution for various life threatening diseases such as cancer, Parkinson, Alzheimer, diabetes, orthopedic problems, diseases related to blood, lungs, neurological, and cardiovascular system.

Development of a new nenomedicine takes several years which are based on various technologies such as dendrimers, micelles, nanocrystals, fullerenes, virosome nanoparticles, nanopores, liposomes, nanorods, nanoemulsions, quantum dots, and nanorobots.

In the field of diagnosis, nanotechnology based methods are more precise, reliable and require minimum amount of biological sample which avoid considerable reduction in consumption of reagents and disposables. Apart from diagnosis, nanotechnology is more widely used in drug delivery purpose due to nanoscale particles with larger surface to volume ratio than micro and macro size particle responsible for higher drug loading. Nano size products allow to enter into body cavities for diagnosis or treatment with minimum invasiveness and increased bioavailability. This will not only improve the efficacy of treatment and diagnosis, but also reduces the side effects of drugs in case of targeted therapy.

Global nanomedicine market is majorly segmented on the basis of applications in medicines, targeted disease and geography. Applications segment includes drug delivery (carrier), drugs, biomaterials, active implant, in-vitro diagnostic, and in-vivo imaging. Global nanomedicine divided on the basis of targeted diseases or disorders in following segment: neurology, cardiovascular, oncology, anti-inflammatory, anti-infective and others. Geographically, nanomedicine market is classified into North America, Europe, Asia Pacific, Latin America, and MEA. Considering nanomedicine market by application, drug delivery contribute higher followed by in-vitro diagnostics. Global nanomedicine market was dominated by oncology segment in 2012 due to ability of nanomedicine to cross body barriers and targeted to tumors specifically however cardiovascular nanomedicine market is fastest growing segment. Geographically, North America dominated the market in 2013 and is expected to maintain its position in the near future. Asia Pacific market is anticipated to grow at faster rate due to rapid increase in geriatric population and rising awareness regarding health care. Europe is expected to grow at faster rate than North America due to extensive product pipeline portfolio and constantly improving regulatory framework.

A Sample of this Report is Available Upon Request @http://www.persistencemarketresearch.com/samples/6370

Major drivers for nanomedicine market include improved regulatory framework, increasing technological know-how and research funding, rising government support and continuous increase in the prevalence of chronic diseases such as obesity, diabetes, cancer, kidney disorder, and orthopedic diseases. Some other driving factors include rising number of geriatric population, awareness of nanomedicine application and presence of high unmet medical needs. Growing demand of nanomedicines from the end users is expected to drive the market in the forecast period. However, market entry of new companies is expected to bridge the gap between supply and demand of nanomedicines. Above mentioned drivers currently outweigh the risk associated with nanomedicines such as toxicity and high cost. At present, cancer is one of the major targeted areas in which nanomedicines have made contribution. Doxil, Depocyt, Abraxane, Oncospar, and Neulasta are some of the examples of pharmaceuticals formulated using nanotechnology.

Request to View Tables of Content @http://www.persistencemarketresearch.com/toc/6370

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

To Know About Latest Report Click Here:http://www.persistencemarketresearch.com/market-research/healthcare-nanotechnology-nanomedicine-market.asp

View original post here:
Healthcare Nanotechnology (Nanomedicine) Market Expected to Generate Huge Profits by 2015 2021: Persistence … – MilTech

Read the Rest...

Nanoparticle delivery tech targets rare lung disease – In-PharmaTechnologist.com

§ July 6th, 2017 § Filed under Nano Medicine Comments Off on Nanoparticle delivery tech targets rare lung disease – In-PharmaTechnologist.com

Researchers at London, UK-based Imperial College are developing a technology to transport drugs directly to the lungs of pulmonary arterial hypertension (PAH) patients.

The technology consists of ethanol-heated iron and trans-trans muconic acid nanoparticles that can be small molecule drug actives.

These particles can be delivered directly to the site of the disease according to lead researcher Jane Mitchell, who told us the targeted approach bypasses the toxicity issues that have held back development of less targeted, systemic nanomedicines.

One of the biggest limitations in nanomedicine is toxicity, some of the best nanomedicine structures do not make it past the initial stages of development, as they kill cells, said Mitchell.

However in a study published in Pulmonary Circulation , researchers explain that these metallic structures – called metal organic frameworks (MOF) are not harmful to cells.

We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells, Mitchell told us.

The hope is that using this approach will ultimately allow for high concentrations of drugs we already have, to be delivered to only the vessels in the lung, and reduce side effects, she said.

Pulmonary arterial hypertension (PAH)

PAH is a rare lung disease caused by changes to the smaller branches of the pulmonary arteries. The artery walls thicken, and eventually cause organ failure.

While no cure exists, treatments that open up blood vessels in the artery wall are available. According to Mitchell, these treatments can produce negative side effects.

The drugs available [for PAH]are all small molecule drugs which are seriously limited by systemic side effects. Therefore delivering these drugs to the site of disease in our metal organic frame-work (MOF) carrier would represent a paradigm step forward in technology to treat this disease, she said.

Further, researchers believe the MOF technology has therapeutic benefits of its own.

We know that the carriers can havetherapeutic benefits intheir own right such as reducing inflammation and, in the case of ourformation, the potential for imaging, said Mitchell.

For patients with PAH, it could mean we are able to turn it from a fatal condition, to a chronic manageable one, she said.

According to Mitchell, the technology is not expensive at the experimental level, and would be scaled up at commercial level.

We now need to perform proof of concept studies using carriers containing drugs in cell and animal based models. With funding, this will be complete within 2 years, she Mitchell.

Upon completion of clinical trials, the University hopes to license out the technology.

Read the original here:
Nanoparticle delivery tech targets rare lung disease – In-PharmaTechnologist.com

Read the Rest...

Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

§ July 6th, 2017 § Filed under Nano Medicine Comments Off on Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

LONDON, July 5, 2017 /PRNewswire/ — “Global Nano Chemotherapy Market & Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.

Download the full report: https://www.reportbuyer.com/product/4884894/

Nano chemotherapy is emerging as an important anti-cancer modality by supplementing the traditional chemotherapy. The main aim of nano chemotherapeutics is to improve the therapeutic efficacy of currently available chemotherapeutic agents by combining it with a nano scale delivery component. The majority of the cancer nanodrugs in the market are liposomes and polymer based nanoformulations which lower the toxicity and enhance the delivery of chemotherapeutics through the passive targeting. It is based on enhanced penetration and retention effect to reduce the lymphatic drainage in tumor tissue.

Conventional chemotherapeutic agents are distributed non-specifically in body where they affect both cancerous and normal cells and thereby it limit the dose availability with in the tumor and also results in suboptimal treatment due to excessive toxicities. To overcome the limitations of chemotherapy treatment, many more therapies has also been emerged.

The use of nanoparticles by both passive and active targeting strategies can enhance the intracellular concentration of drugs in cancer cells while avoiding the toxicity in normal cells. When the nanoparticles bind to a specific receptors and then enter the cell, usually enveloped by endosomes through receptor mediated endocytosis and thereby bypassing the recognition of P glycoprotein.

Nanomedicine has already met with success in oncology domain with various product commercially available in the market. By releasing the efficacy of nanomedicine in oncology, it increases the interest of the market players to commercialize the products in the field of nanotherapeutics and helps to increase the global market. The future of nanotherapeutics is bright and especially for the reversible cross linked nano carriers which are decorated with the cancer targeting ligands and it promote the endocytic uptake in tumor cells. The approach has the potential to overcome the drug resistance which is often with conventional chemotherapies.

For the next generation cancer nanotherapeutics, the complexity is higher which are under clinical development in terms of hybrid structures, surface physiochemical characteristics and mechanisms of delivery and action. There have been rapid advances in the nano therapeutic field in the past decade. Many of the nano carriers have been developed from which some have the great therapeutic potential. However, there remain many challenges in translating the nanoparticle drugs into the clinics. Download the full report: https://www.reportbuyer.com/product/4884894/

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: http://www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-nano-chemotherapy-market–clinical-trials-outlook-2022-300483678.html

More:
Global Nano Chemotherapy Market & Clinical Trials Outlook 2022 – PR Newswire (press release)

Read the Rest...

Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

§ July 5th, 2017 § Filed under Nano Medicine Comments Off on Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

New research from Imperial College London, that has recently been published online, examined a novel type of nanoparticle called metal organic frameworks (MOF) as drug carriers for the treatment of pulmonary arterial hypertension (PAH).

Published in Pulmonary Circulation, the research describes the first steps in the development of nanoparticles that can deliver drugs directly to the lungs. The MOFs, created in the laboratory by the researchers, are composed of iron and can expand to create pores within which drugs used to treat PAH can be stored and released where needed.

The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects, explained Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial in a news release. For patients with PAH, it could mean we are able to turn it from a fatal condition, to a chronic manageable one.

When testing the MOFs, the team from Imperial found that the structures reduced inflammation and were not toxic to human lung cells and blood vessels in laboratory conditions. Further testing in rats, showed the MOFs were safe in the animal model over a two-week period with few side-effects a slight build-up of iron was seen in the liver.

One of the biggest limitations in nanomedicine is toxicity, some of the best nanomedicine structures do not make it past the initial stages of development as they kill cells, continued Mitchell. We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells.

The aim is to develop the metallic structures as a drug delivery method where the framework can hold onto the drug and release it under specific conditions, such as a change in pH, temperature or using magnets external to the body to draw the MOFs to the target area. Next steps for this research is to discover the ideal way to get the tiny structures loaded with drugs and delivered to the lungs effectively.

In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung, Mitchell concluded. This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery.

See the original post:
Metallic nanomolecules could help treat fatal lung disease in the future, notes research – EPM Magazine

Read the Rest...

Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

§ July 3rd, 2017 § Filed under Nano Medicine Comments Off on Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

July 3, 2017 by Ryan O’hare Nanomedicine could help patients with fatal lung conditions. Credit: Imperial College London

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

Scientists based at Imperial College London have tested a new type of nanoparticle called metal organic frameworks (MOF) tiny metal cages less than 100 nanometres across that can be loaded with drug molecules which they believe could potentially be used to treat patients with a devastating condition called pulmonary arterial hypertension (PAH).

In PAH the blood vessels of the lungs constrict and thicken, increasing blood pressure and causing the right side of the heart to work harder and harder, until it eventually fails. The condition is rare but devastating and can affect people of all ages, including babies, young adults and the elderly. Patients in the late stage of the disease have few treatment options beyond transplant, with a mean survival time of around five years following diagnosis.

While there is no cure for PAH, existing treatments work by opening up these blood vessels. These drugs act on blood vessels throughout the body, however, causing blood pressure to drop and resulting in a number of side effects which means the dose at which these drugs can be given is limited.

In their latest study, published online in Pulmonary Circulation, the multidisciplinary group at Imperial describes how it has taken the first in a number of steps to develop nanoparticles which could deliver drugs directly to the lungs, showing that the basic structures are not harmful to cells.

Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial, who led the research, said: “The hope is that using this approach will ultimately allow for high concentrations of drugs we already have to be delivered to only the vessels in the lung, and reduce side effects. For patients with pulmonary arterial hypertension, it could mean we are able to turn it from a fatal condition, to a chronic manageable one.”

Metallic cages for drug delivery

The tiny metallic structures composed of iron were made in the lab of Professor Paul Lickiss and Dr Rob Davies’s, from the Department of Chemistry and by Dr Nura Mohamed during her PhD studies at Imperial. Dr Mohamed, who was funded by the Qatar Foundation, made the structures so existing drugs used to treat PAH could fit inside them.

These structures were tested in human lung cells and blood vessel cells, which were grown from stem cells in the blood of patients with PAH. The team found that the structures reduced inflammation and were not toxic to the cells.

Further tests showed that the MOFs were safe in rats, with animals injected with MOFs over a two-week period showing few side effects other than a slight build-up of iron in the liver.

“One of the biggest limitations in nanomedicine is toxicity, some of best nanomedicine structures do not make it past the initial stages of development as they kill cells,” said Professor Mitchell. “We made these prototype MOFs, and have shown they were not toxic to a whole range of human lung cells.”

MOFs are an area of interest in nanomedicine, with engineers aiming to develop them as carriers which can hold onto drug cargo, releasing it under specific conditions, such as changes in pH, temperature, or even when the nanostructures are drawn to the target area by magnets outside the body.

Beyond the finding that their iron nanostructures were non-toxic, the team believes the MOFs may have additional therapeutic properties. There was evidence to suggest anti-inflammatory properties, with the MOFs reducing the levels of an inflammatory marker in the blood vessels, called endothelin-1, which causes arteries to constrict. In addition, iron is also a contrast agent, meaning it would show up on scans of the lungs to show where the drug had reached.

The MOFs have not yet been tested in patients, but the next step is to load the tiny metallic structures with drugs and work out the best way to get them to target their cargo to the lungs. The researchers are confident that if successful, the approach could move to trials for patients, with a drug candidate ready to test within the next five years. The MOFs could potentially be delivered by an inhaler into the lung, or administered by injection.

“In this study we have proved the principle that this type of carrier has the potential to be loaded with a drug and targeted to the lung,” explained Professor Mitchell. “This is fundamental research and while this particular MOF might not be the one that makes it to a drug to treat PAH, our work opens up the idea that this disease should be considered with an increased research effort for targeted drug delivery.”

Explore further: Longer-lasting pain relief with MOFs

More information: Nura A. Mohamed et al. Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy, Pulmonary Circulation (2017). DOI: 10.1177/2045893217710224

To treat headaches, back pain or fever, most of us have reached for ibuprofen at one point or another. But we often have to take doses every four to six hours if the pain warrants it. Now scientists are working on a way to …

People with a lung scarring condition that leaves them fighting for breath could be helped by a new medication, research suggests.

A recent US study of people treated for cancer as children from the 1970s to 1999 showed that although survival rates have improved over the years, the quality of life for survivors is low. It also showed this was worse for …

(HealthDay)Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary …

(Medical Xpress) — Scientists at UCD have identified a potential new treatment for life-threatening complications associated with chronic obstructive lung diseases like emphysema and chronic bronchitis. Chronic obstructive …

(Phys.org)One of the most promising microscale power sources for portable and wearable electronics is a micro-supercapacitorthey can be made thin, lightweight, highly flexible, and with a high power density. Normally, …

Metallic nanomolecules capable of carrying drugs to exactly where they are needed could one day help to treat patients with a fatal lung condition.

The possibility of looking inside silicon chips to see their tiny working parts, without damaging the chips, is a step closer thanks to an international team led by scientists at the LCN.

Science fiction is full of fanciful devices that allow light to interact forcefully with matter, from light sabers to photon-drive rockets. In recent years, science has begun to catch up; some results hint at interesting …

Dialysis, in the most general sense, is the process by which molecules filter out of one solution, by diffusing through a membrane, into a more dilute solution. Outside of hemodialysis, which removes waste from blood, scientists …

Rice University scientists have fabricated a durable catalyst for high-performance fuel cells by attaching single ruthenium atoms to graphene.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Excerpt from:
Nano-sized drug carriers could be the future for patients with lung disease – Phys.Org

Read the Rest...

Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

§ June 30th, 2017 § Filed under Nano Medicine Comments Off on Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

June 30, 2017 Size switchable nano-theranostics constructed with decomposable inorganic nanomaterials for acidic TME targeted cancer therapy. (a) A scheme showing the preparation of HSA-MnO2-Ce6&Pt (HMCP) nanoparticles, and (b) their tumor microenvironment responsive dissociation to enable efficient intra-tumoral penetration of therapeutic albumin complexes. (c) A scheme showing the preparation of Ce6(Mn)@CaCO3-PEG, and (d) its acidic TME responsive dissociation for enhanced MR imaging and synergistic cancer therapy. Credit: Science China Press

Cancer is one of leading causes of human mortality around the world. The current mainstream cancer treatment modalities (e.g. surgery, chemotherapy and radiotherapy) only show limited treatment outcomes, partly owing to the complexities and heterogeneity of tumor biology. In recent decades, with the rapid advance of nanotechnology, nanomedicine has attracted increasing attention as promising for personalized medicine to enable more efficient and reliable cancer diagnosis and treatment.

Unlike normal cells energized via oxidative phosphorylation, tumor cells utilize the energy produced from oxygen-independent glycolysis for survival by adapting to insufficient tumor oxygen supply resulting from the heterogeneously distributed tumor vasculatures (also known as the Warburg effect). Via such oncogenic metabolism, tumor cells would produce a large amount of lactate along with excess protons and carbon dioxide, which collectively contribute to enhanced acidification of the extracellular TME with pH, often in the range of 6.5 to 6.8, leading to increased tumor metastasis and treatment resistance.

With rapid advances in nanotechnology, several catalogs of nanomaterials have been widely explored for the design of cancer-targeted nano-theranostics. In a new overview published in the Beijing-based National Science Review, co-authors Liangzhu Feng, Ziliang Dong, Danlei Tao, Yicheng Zhang and Zhuang Liu at the Institute of Functional Nano & Soft Materials (FUNSOM), Soochow University in Suzhou, China present new developments in the design of novel multifunctional nano-theranostics for precision cancer nanomedicine by targeting the acidic TME and outline the potential development directions of future acidic tumor microenvironment-responsive nano-theranostics.

“Various types of pH-responsive nanoprobes have been developed to enable great signal amplification under slightly reduced pH within solid tumors. By taking the acidic TME as the target, smart imaging nanoprobes with excellent pH-responsive signal amplification would be promising to enable more sensitive and accurate tumor diagnosis,” they state in the published study.

“As far as nano-therapeutics are concerned, it has been found that the acidic TME responsive surface charge reverse, PEG corona detachment and size shrinkage (or decomposition) of nanoparticles would facilitate the efficient tumor accumulation, intra-tumoral diffusion and tumor cellular uptake of therapeutics, leading to significantly improved cancer treatment. Therefore, the rational development of novel cancer-targeted nano-theranostics with sequential patterns of size switch from large to small, and surface charge reverse from neutral or slightly negative to positive within the tumor, would be more preferred for efficient tumor-targeted drug delivery.”

The scientists also write, “For the translation of those interesting smart pH-responsive nano-therapeutics from bench to bedside, the formulation of those nanoscale systems should be relatively simple, reliable and with great biocompatibility, since many of those currently developed nano-theranostics were may be too complicated for clinical translation.”

Explore further: Treatment with Alk5 inhibitor improves tumor uptake of imaging agents

More information: Liangzhu Feng et al, The acidic tumor microenvironment: a target for smart cancer nano-theranostics, National Science Review (2017). DOI: 10.1093/nsr/nwx062

A form of genetic variation, called differential RNA splicing, may have a role in tumor aggressiveness and drug resistance in African American men with prostate cancer. Researchers at the George Washington University (GW) …

While mutations in protein-coding genes have held the limelight in cancer genomics, those in the noncoding genome (home to the regulatory elements that control gene activity) may also have powerful roles in driving tumor …

A molecular test can pinpoint which patients will have a very low risk of death from breast cancer even 20 years after diagnosis and tumor removal, according to a new clinical study led by UC San Francisco in collaboration …

Scientists have had limited success at identifying specific inherited genes associated with prostate cancer, despite the fact that it is one of the most common non-skin cancers among men. Researchers at University of Utah …

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

Follicular lymphoma is an incurable cancer that affects over 200,000 people worldwide every year. A form of non-Hodgkin lymphoma, follicular lymphoma develops when the body starts making abnormal B-cells, which are white …

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Visit link:
Exploiting acidic tumor microenvironment for the development of novel cancer nano-theranostics – Medical Xpress

Read the Rest...

MagForce AG Publishes Financial Results for the Year 2016 and Operative Highlights – Baystreet.ca

§ June 30th, 2017 § Filed under Nano Medicine Comments Off on MagForce AG Publishes Financial Results for the Year 2016 and Operative Highlights – Baystreet.ca

[ACCESSWIRE]

– Continued Expansion of Commercialization of NanoTherm Therapy for the Treatment of Brain Tumors in Europe; Obtaining Domestic Reimbursement Ahead and Streamlined Implementation of Cross-Border Process – Second Clinical Treatment Site for the Treatment of Intermediate Prostate Cancer in the US Established at CHRISTUS Santa Rosa Hospital – Medical Center in San Antonio, Texas; IDE Approval Process with the FDA Progressing – Successful Capital Increase with Renowned UK-Based M&G International Investments with Gross Proceeds of EUR 5.0 Million Mainly to Accelerate the On-Going International Expansion (After Period-End)

BERLIN, GERMANY and NEVADA / ACCESSWIRE / June 30, 2017 / MagForce AG (FRA: MF6, Scale: MF6, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results as of and for the year ended December 31, 2016 as well as operative highlights.

Operative Highlights:

Treatment of Brain Cancer in Europe:

MagForce AG is continuing to expand the commercialization of its innovative NanoTherm therapy for the treatment of brain cancer in Europe. In their quest to improve patient care, the neurosurgeons applying NanoTherm therapy for the treatment of brain tumors continue to find additional medical benefits when NanoTherm therapy is incorporated into their primary treatment regimen.

MagForce presented at many renowned conferences and congresses, which increases the awareness of its unique therapy within the main target groups, such as the medical community, patient advocacy groups, patients, their relatives, and caregivers. The Company is also increasingly receiving positive feedback from patients regarding their experiences with the NanoTherm therapy.

During 2016, MagForce has streamlined the implementation of the cross-border reimbursement process, however, due to the aggressiveness of glioblastoma, there is a limited time interval to achieve treatment. In order to give patients the benefit from the NanoTherm treatment, the Company continues to increase the medical awareness of the value of NanoTherm therapy to encourage patients and neurosurgeons to consider NanoTherm therapy earlier following the diagnosis of their tumor status.

The current roll-out plan sees MagForce placing its NanoActivator devices in a number of European countries and thus enabling patients to be treated in their home countries. Facilitating treatment of patients in their home countries will also simplify reimbursement in those countries where MagForce already has the CE mark approval for the treatment of brain tumors. Amongst others, MagForce’s commercial and medical teams have identified Poland, Italy, Switzerland, and Spain as suitable countries for NanoTherm treatment centers.

At the same time, MagForce is in the process of obtaining domestic reimbursement for NanoTherm therapy in Germany.

Treatment of Intermediate Risk Prostate Cancer in the USA:

MagForce USA, Inc. had filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA) for NanoTherm therapy to treat Intermediate Risk Prostate Cancer. During 2016, MagForce USA repeated and updated the pre-clinical studies (originally conducted in Germany about 10 years ago) with its clinical NanoActivator installed at University of Washington 2015.

The results of these pre-clinical studies and the proposed clinical trial protocol were submitted to the FDA in late fourth quarter, 2016. An in-person follow-up meeting with FDA representatives was held in early January 2017 to discuss MagForce’s submissions and identify required clarification. This meeting was again very productive and MagForce believes it can successfully address their questions.

MagForce plans another in-person meeting with the FDA in the near future to determine if its proposed approach to address their requests is accepted.

The key to achieving the Company’s goals is to continue to establish clinical treatment sites and obtain the necessary administrative approvals. MagForce has completed the installation of the NanoActivator at a second site located at CHRISTUS Santa Rosa Hospital – Medical Center in San Antonio, Texas.

While MagForce is now approximately six months behind schedule, the Management is still confident and will make every effort to achieve its original targets in terms of market entry and commercialization of NanoTherm therapy in the USA – which is projected for 2018.

Results of Operations, Net Assets, and Financial Position

Non-GAAP financial measures are used by MagForce’s management to make operating decisions because they facilitate internal comparisons of MagForce’s performance to historical results. The Non GAAP measures are presented in the year-end financial publication as MagForce’s management believes that they will provide investors with means of evaluating, and an understanding of how MagForce’s management evaluates, MagForce’s performance and results on a comparable basis that is not otherwise apparent on a German GAAP basis, since many non-recurring, infrequent or non-cash items that MagForce’s management believes are not indicative of the core performance of the business may not be excluded when preparing financial measures under German GAAP.

These Non-GAAP measures should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with German GAAP.

Net Loss for the business year was EUR 7,231 thousand (prior year: EUR 1,547 thousand). Non-GAAP net loss remained almost stable at EUR 5,107 thousand (prior year: EUR 5,050 thousand).

Compared to the prior year period personnel expenses increased by EUR 262 thousand to EUR 3,252 thousand (prior year: EUR 2,990 thousand) due to an increased average number of employees in 2016 (29; prior year: 23).

Revenue and Other Operating Income amounted to EUR 1,581 thousand (prior year: EUR 7,702), while Non-GAAP revenue and other operating income increased by EUR 136 thousand to EUR 1,581 thousand (prior year: EUR 1,445 thousand). The Non-GAAP increase chiefly stems from higher recharges to subsidiaries. Revenue and other operating income were adjusted to arrive at Non-GAAP figures by the prior-year amounts resulting from the extension of the distribution and development rights for the countries Canada and Mexico in January 2015 (EUR 3,033 thousand), the sale of four NanoActivator devices to MagForce USA, Inc. (EUR 2,421 thousand) and by the write-up of the loans of MT MedTech GmbH (EUR 803 thousand).

Other operating expenses increased to EUR 4,309 thousand (prior year: EUR 3,173 thousand), while Non-GAAP operating expenses remained almost stable at EUR 6,918 thousand (prior year: EUR 6,824 thousand). Other operating expenses were adjusted for the impairment of the loans to MT MedTech GmbH in the amount of EUR 1,218 thousand (prior year: nil) to arrive at Non-GAAP.

Cash outflows from operating activities amounted to EUR -6,575 thousand (prior year: EUR -5,185 thousand).

Cash inflows from investing activities amounted to EUR 3,073 thousand (prior year: Cash outflow of EUR -2,575 thousand). Cash inflows for the year 2016 are largely due to repayments of short-term loans in the amount of EUR 3,000 thousand. Cash flows from financing activities amounted to EUR 2,723 (prior year: EUR nil).

Cash and cash equivalents as of December 31, 2016 amounted to EUR 614 thousand (prior year: EUR 1,393 thousand).

Capital Market Transactions and Funding of the Company After the End of Period

To improve liquidity and to ensure the development of new products beyond 2017 the Company issued a EUR 5.0 million convertible loan on March 2, 2017, with a maturity of 3 years, an interest rate of 5% p.a., and a conversion price at EUR 5.00 per share. Furthermore, Lipps & Associates LLC continues providing lines of funds to support expansion plans as a means of non-dilutive funding.

In addition on June 28, 2017, MagForce AG resolved and successfully implemented a capital increase from authorized capital. The Company’s share capital will, therefore, be increased from EUR 25,622,711.00 to EUR 26,343,172.00 by issuing 720,461 new no-par-value shares at a price of EUR 6,94 per share by partially utilizing existing authorized capital against cash contributions. All new shares were subscribed by UK-based M&G International Investments Ltd. in a private placement. Gross proceeds for MagForce AG amount to EUR 5.0 million. The additional capital will be mainly used to accelerate the on-going international expansion of MagForce, in particular in Europe.

Outlook and Financial Prognosis 2017 and Beyond

In 2017, MagForce will focus on establishing an expansion strategy in Europe for the treatment of brain tumors, initiating a study to ensure refund of treatment expenses in selected European countries, starting the clinical study for marketing authorization for the treatment of prostate cancer in the US and initiating the production of related ambulatory NanoActivator devices.

The Company expects an extension of its business activity due to the planned expansion strategy in Europe. This is accompanied by a study to ensure reimbursement of treatment expenses in participating countries. As a result from the increased activity, MagForce expects higher commercial expenses and in 2018 an increased net loss.

For the years 2017 and 2018, the Company plans to intensify cooperation with local and international patient organizations to further establish NanoTherm therapy and to increase the number of patient inquiries. Furthermore, new ways for reimbursement in Germany and selected countries will be established to make NanoTherm therapy available to as many patients as possible. Also, the Company plans to enhance its presence at appropriate events and with foreign patient organizations. MagForce’s management has executed the necessary measures and set up a plan to finance the Company’s expansion targets for Europe in 2017 and 2018.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm(R) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.com.

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects,” “aims,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” or “will.” Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in the case of developments, which differ from those, anticipated.

Contact:

Barbara von Frankenberg Vice President Communications & Investor Relations T +49-30-308380-77 E-Mail: bfrankenberg@magforce.com

SOURCE: MagForce AG via the EQS Newswire distribution service including Press Releases and Regulatory Announcements

See more here:
MagForce AG Publishes Financial Results for the Year 2016 and Operative Highlights – Baystreet.ca

Read the Rest...

NanoViricides (NNVC) Abstract Accepted for Poster Presentation at ASV – StreetInsider.com

§ June 20th, 2017 § Filed under Nano Medicine Comments Off on NanoViricides (NNVC) Abstract Accepted for Poster Presentation at ASV – StreetInsider.com

Get daily under-the-radar research with StreetInsider.com’s Stealth Growth Insider Get your 2-Wk Free Trial here.

NanoViricides, Inc., (NYSE: NNVC) a pioneer in developing anti-viral nanomedicine drugs, is pleased to announce that its late-breaking abstract submission has been accepted for a poster presentation at the 36th Annual Meeting of the American Society of Virology (ASV). The ASV Meeting will be hosted and held at the University of Wisconsin-Madison, from June 24th to 28th, 2017 (https://extensionconferencecenters.uwex.edu/asv2017/).

Dr. Brian Friedrich, Senior Virologist of the Company, will present the Company’s work on the evaluation of nanoviricides drug candidates for effectiveness against the shingles virus (Varicella Zoster Virus, VZV, aka Human HerpesVirus-3 or HHV-3). He will present data on both safety and effectiveness of the nanoviricides drug candidates against VZV infection in multiple different cell lines.

NanoViricides has recently announced that two of the HerpeCide program drug candidates demonstrated complete (almost 100%) inhibition of the varicella-zoster virus (VZV, aka human herpesvirus 3 or HHV-3) at highest drug doses, whereas acyclovir at the same drug dose exhibited only about 70% inhibition of the virus. The nanoviricide drug candidates were almost five times as effective as acyclovir in these assays. No cytotoxicity was observed at any of the doses tested for the herpecide drug candidates. Details of these studies will be presented in the poster at the 2017 Annual Meeting of the ASV.

The NanoViricides poster, entitled “Novel Nanoviricides Highly Effective against Varicella Zoster Virus in Cell Culture” will be presented in Poster Session II, open for viewing from 4pm to 6pm on Monday, June 26th, 2017.

About NanoViricides: NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

Read more:
NanoViricides (NNVC) Abstract Accepted for Poster Presentation at ASV – StreetInsider.com

Read the Rest...

Nanomedicine Global Market Outlook,Research,Trends and Forecast to 2023 – Digital Journal

§ June 20th, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine Global Market Outlook,Research,Trends and Forecast to 2023 – Digital Journal

WiseGuyReports.Com Publish a New Market Research Report On – Nanomedicine Global Market Outlook,Research,Trends and Forecast to 2023.

This press release was orginally distributed by SBWire

New York, NY — (SBWIRE) — 06/19/2017 — Overview: Nanomedicine is an offshoot of nanotechnology, and refers to highly-specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. Nanomedicine uses nano-sized tools for the diagnosis, prevention and treatment of disease, and to gain increased understanding of the complex underlying pathophysiology of the disease. It involves three nanotechnology areas of diagnosis, imaging agents, and drug delivery with nanoparticles in the 11,000 nm range, biochips, and polymer therapeutics.

The majority of nanomedicines used now allow oral drug delivery and its demand is increasing significantly. Although these nanovectors are designed to translocate across the gastrointestinal tract, lung, and bloodbrain barrier, the amount of drug transferred to the organ is lower than 1%; therefore improvements are challenging. Nanomedicines are designed to maximize the benefit/risk ratio, and their toxicity must be evaluated not only by sufficiently long term in vitro and in vivo studies, but also pass multiple clinical studies.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/1273888-global-nanomedicine-market-drivers-opportunities-trends-and-forecasts-2017-2023

For more information or any query mail at sales@wiseguyreports.com

Market Analysis: The “Global Nanomedicine Market” is estimated to witness a CAGR of 17.1% during the forecast period 20172023. The nanomedicine market is analyzed based on two segments therapeutic applications and regions.

Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is set to be the leading region for the nanomedicine market growth followed by Europe. The Asia Pacific and ROW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various nano-drugs are expected to increase in the coming years. The major countries covered in this report are the US, Germany, Japan, and Others.

Therapeutic Application Analysis: Nanomedicines are used as fluorescent markers for diagnostic and screening purposes. Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Players: Merck & Co. Inc., Hoffmann-La Roche Ltd., Gilead Sciences Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, Sanofi, Nanobiotix SA, UCB SA and other predominate & niche players.

Competitive Analysis: At present, the nanomedicine market is at a nascent stage but, a lot of new players are entering the market as it holds huge business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of nanoparticles and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits: The report provides complete details about the usage and adoption rate of nanomedicines in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives towards the nanomedicine adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Ask Query @ https://www.wiseguyreports.com/enquiry/1273888-global-nanomedicine-market-drivers-opportunities-trends-and-forecasts-2017-2023

Table Of Contents Major Key Points

1 Industry Outlook 10 1.1 Industry Overview 10 1.2 Industry Trends 11 1.3 PEST Analysis 12

2 Report Outline 12 2.1 Report Scope 12 2.2 Report Summary 13 2.3 Research Methodology 14 2.4 Report Assumptions 14

3 Market Snapshot 16 3.1 Total Addressable Market (TAM) 16 3.2 Segmented Addressable Market (SAM) 16 3.3 Related Markets 17 3.3.1 mHealth Market 17 3.3.2 Healthcare Analytics Market 18

4 Market Outlook 18 4.1 Overview 18 4.2 Regulatory Bodies and Standards 19 4.3 Government Spending and Initiatives 19 4.4 Porter 5 (Five) Forces 21

5 Market Characteristics 22 5.1 Evolution 22 5.2 Ecosystem 25 5.2.1 Regulatory Process 25 5.2.2 Clinical Trials 25 5.2.3 Pricing and Reimbursement 26 5.3 Market Segmentation 28 5.4 Market Dynamics 28 5.4.1 Drivers 29 5.4.1.1 Emergence of nanorobotics 29 5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments 29 5.4.1.3 Reasonable investments in R&D 30 5.4.1.4 Increased support from governments 30 5.4.2 Restraints 31 5.4.2.1 Long approval process and stringent regulations 31 5.4.2.2 Problems regarding nanoscale manufacturing 31 5.4.2.3 Risks related to nanomedicines 31 5.4.2.4 Undefined regulatory standards 31 5.4.3 Opportunities 32 5.4.3.1 Aging population with chronic care needs 32 5.4.3.2 Population and income growth in emerging countries 32 5.4.4 DRO Impact Analysis 33

6 Trends, Roadmap and Projects 34 6.1 Market Trends and Impact 34 6.2 Technology Roadmap 35

7 Types: Market Size and Analysis 36 7.1 Overview 36 7.2 Global Nanomedicine Market in Oncology Segment 37 7.3 Global Nanomedicine Market in Cardiovascular Segment 38 7.4 Global Nanomedicine Market in Neurology Segment 39 7.5 Global Nanomedicine Market in Anti-inflammatory Segment 39 7.6 Global Nanomedicine Market in Anti-infective Segment 40 7.7 Global Nanomedicine Market in Other Therapeutic Areas 41

8 Trending Nanomedicines 42 8.1 Overview 42 8.2 Abraxane 43 8.3 Alimta 43 8.4 Eligard 44 8.5 Copaxone 44 8.6 Rapamune 44 8.7 Neulasta 45 8.8 Cimzia 45 8.9 AmBisome 46 8.10 Mircera 46 8.11 Pegasys 46 8.12 Emend 47 8.13 Renagel 47 8.14 Ritalin 47

For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1273888

About Wise Guy Reports Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

For more information on this press release visit: http://www.sbwire.com/press-releases/nanomedicine-global-market-outlookresearchtrends-and-forecast-to-2023-816726.htm

See original here:
Nanomedicine Global Market Outlook,Research,Trends and Forecast to 2023 – Digital Journal

Read the Rest...

2017 Forecast – Asia Pacific Nanomedicine Market, Industry Size and Share to 2023 – Digital Journal

§ June 20th, 2017 § Filed under Nano Medicine Comments Off on 2017 Forecast – Asia Pacific Nanomedicine Market, Industry Size and Share to 2023 – Digital Journal

Global Market Research Report on Nanomedicine Market 2017 is a professional and in-depth complete study on the current state of the Nanomedicine worldwide.

This press release was orginally distributed by SBWire

Deerfield Beach, FL — (SBWIRE) — 06/19/2017 — Latest industry research report on Nanomedicine Market. Nanomedicine is the applied branch of nanotechnology. Application of nanomedicines ranges from nonmaterial to nanoelectronic and in the near future, it could possibly expand to molecular nanotechnology. Biological, pharmaceutical and medical research organizations (CROs) are largely benefitted by the exceptional properties of nonmaterial and exploit it for various applications including diagnosis and treatment of diseases. The Asia pacific nanomedicine market is majorly driven by advancement in nanomedicine technologies, government initiatives, growing investment in research funding, better understanding of technical know-how and a high prevalence of chronic diseases.

Get Free Sample Report Of Nanomedicine Market @ http://www.marketresearchstore.com/report/asia-pacific-nanomedicine-market-opportunities-and-forecasts-71378#RequestSample

However, the cost of materials used in nanotechnology study along with the insufficient regulatory framework can pose a major restrain for the growth of the Asia pacific nanomedicines market. Presence of high growth opportunities in nanomedicines would provide significant benefits to emerging economies such as India and China due to the impending healthcare needs in this location.

The Asia Pacific nanomedicine market is segmented into two categories such as application and geography.

BY APPLICATION

Cardiovascular Oncology Anti-Inflammatory Anti-Infective Neurology Others

BY GEOGRAPHY

China Japan India Australia Others

Do Inquiry To Buy Report Of Nanomedicine Market @ http://www.marketresearchstore.com/report/asia-pacific-nanomedicine-market-opportunities-and-forecasts-71378#InquiryForBuying

For more information on this press release visit: http://www.sbwire.com/press-releases/2017-forecast-asia-pacific-nanomedicine-market-industry-size-and-share-to-2023-813182.htm

Read more here:
2017 Forecast – Asia Pacific Nanomedicine Market, Industry Size and Share to 2023 – Digital Journal

Read the Rest...

Editor’s choice: recent research highlights from the International Journal of Nanomedicine – Dove Medical Press

§ June 20th, 2017 § Filed under Nano Medicine Comments Off on Editor’s choice: recent research highlights from the International Journal of Nanomedicine – Dove Medical Press

Farooq A Shiekh,1 Abdul-Rahman M Abu-Izzah,2 Vivian J Lee,2 Syed Mudassar1

1Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, India; 2Department of Basic Medical Sciences, Avalon University School of Medicine, Curacao, the Netherlands Is nanomedicine really less harmful? Evaluation of: Thakkar A, Chenreddy S, Thio A, Khamas W, Wang J, Prabhu S. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine. 2016;11:32653276. Nanomedicine1 has increasingly received a tremendous attention over the past two decades as a potential multidimensional field, developing nano-applications that are transforming a host of medical products and services,2,3 including drug delivery4 and health-monitoring devices, and the possibility of gaining new insights about undruggable targets and treatment through atomic-scale precision is increasing rapidly.5 Although it is uncertain as to which of the new delivery platforms will become the most effective and useful, it is certain that many new approaches will be investigated in the years to come.4,6

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original here:
Editor’s choice: recent research highlights from the International Journal of Nanomedicine – Dove Medical Press

Read the Rest...

Nanomedicine and Drug Delivery Conferences | Pharma …

§ June 13th, 2017 § Filed under Nano Medicine Comments Off on Nanomedicine and Drug Delivery Conferences | Pharma …

About Us

International Conference and Exhibition on Nanomedicine and Drug Delivery May 14-16, 2018 Tokyo, Japan

ConferenceSeries Ltdis a renowned organization that organizes highly notable Pharmaceutical Conferencesthroughout the globe. Currently we are bringing forthInternational Conference on Nanomedicine and Drug Delivery(NanoDelivery 2018) scheduled to be held duringMay 14-16, 2018 at Tokyo, Japan. The conferenceinvites all the participants across the globe to attend and share their insights and convey recent developments in the field of Nanomedicine and Drug Delivery.

ConferenceSeries Ltdorganizes aconference seriesof 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientificsocietiesand publishes 700+Open access Journalswhich contains over 50000 eminent personalities, reputed scientists as editorial board members.

2018 Highlights:

Nanomedicine and drugdelivery will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nano medicine and drug delivery respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as Japan, China, India and other economies in the region. Japan is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.This conference seeks to showcase work in the area of Nanomedicine, Drug Delivery Systems, and nanotechnology, Nanobiothechnology, particularly related to drug delivery.

For More PS: http://nanomedicine.pharmaceuticalconferences.com/

(Click here for any queries)

Nanomedicine and drugdelivery can address one of the greatest challenges in the post-genomic era of the 21st century making the essential connections between Academics and industry professionals.

To meet these challenges, the field of Nanomedicine and drugdelivery has undergone exponential growth during the last 5 years. Technologies such as Personalized Nanomedicine, Nanomedicine in Theranostics, Design of Nanodrugs, Synthesis of Nanoparticles for Drug Delivery, Regenerative Medicine and Tissue Engineering, Nanomedicines and Biomedicalapplications, Nanomaterials for drug delivery, Regulatory Aspects Towards Approval of Nanomedicine, NanoPharmaceutical Industry and Market processing and drug delivery promise to transform the world of nanomedicines and drug delivery much in the same way that integrated a transformed the world of pharmaceutical sciences.

Nanodelivery 2018 has everything you need:

Open panel discussions: Providing an open forum with experts from academia and business to discuss on current challenges in nanomedicine and drugdelivery, where all attendees can interact with the panel followed by a Q&A session.

Speaker and poster presentations: Providing a platform to all academicians and industry professionals to share their research thoughts and findings through a speech or a poster presentation.

Editorial board meeting: Discussing on growth and development of open access Nanomedicine and drugdelivery International Journals and recruiting board members and reviewers who can support the journal.

Round table meetings: Providing a platform where industry professionals meet academic experts.

Over 50+ organizations and international pavilions will be exhibiting at the Nanodelivery 2017 conference and Exhibition. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will see at the Nanodelivery Exhibition, you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from todays industry leaders.

The Nanodelivery 2017 has everything you need, all under one roof, saving you both time and money. It is the event you cannot afford to miss!

Who’s Coming to Nanodelivery 2018?

More:
Nanomedicine and Drug Delivery Conferences | Pharma …

Read the Rest...

A method to improve in vitro tests – Phys.Org

§ June 9th, 2017 § Filed under Nano Medicine Comments Off on A method to improve in vitro tests – Phys.Org

June 6, 2017

Before new nanoparticles or other nanomedicines can be injected into the human body, a whole series of tests must be conducted in the laboratory, then in living cells, and in the end on humans. But often the results obtained in vitro do not resemble what actually happens in the animal or human body. Thus, the researchers reconsidered the basis of the in vitro experimental design.

In an article published in the journal Small, EPFL researchers explain how such issues can be avoided by replacing conventional static in vitro tests with dynamic tests that approximate complex living conditions – comparable to those that occur in the body’s blood and lymphatic systems.

The researchers were able to “replicate” the varying real-body conditions in a lab, and test the behaviour of nanoparticles in different blood and lymph flows. They also reproduced the “cleaning” effect of nanoparticles, which go through in lymph nodes, by “washing” lymph off them and reinjecting them into the blood serum.

“Current incubation conditions are static,” says Marijana Mionic Ebersold, a former post-doc at EPFL, leading author of the study in the framework of a Nano-Tera project and currently working as a scientific collaborator at the University Hospital of Lausanne (CHUV). “Nanoparticles or drugs to be tested are carefully added to the typically static fluids and cells, and then there is a waiting period in static conditions before the interaction and the effects can be studied for instance under the microscope”, she adds. “In the human body, fluids and cells never stay nicely static. It’s an extremely dynamic and complex environment. The conventional static in vitro methods do not therefore allow for the translation of results from in vitro to in vivo testing.”

Reproducing the conditions in blood and lymphatic systems

For their study, the researchers used the protein corona as the parameter which reflects this in vitro/in vivo discrepancy. The protein corona forms around nanoparticles when they come into contact with a biological environment. Its presence influences the behaviour of nanoparticles in the body by altering their chemical properties, destination, and their interactions with other cells.

The protein corona is affected by both the flow and type of fluid, i.e. blood or lymph, as the study shows. “Surprisingly, the influence of lymph on the protein corona and the fate of nanoparticles has so far been completely neglected – although subcutaneously injected nanomedicines immediately contact the patient’s lymph”, says Mioni? Ebersold.

The study revealed that a change in both the flow and fluids is an extremely important factor when it comes to the formation of the protein corona. For example, the flow conditions would change and the protein corona would be different in a patient with different blood pressure troubles as compared to a healthy person. Nanoparticles may thus behave quite differently and in various patients and have different effects on them.

Dynamic tests would therefore be extremely useful for observing the formation of the protein corona in various in vitro environments in order to predict how the nanoparticles will ultimately behave in vivo. “When in vivo results are different to in vitro results, scientists tend to say that they tested their nanomedicine in the wrong animal model or that the chemicals weren’t exactly the same etc.,” says Mioni? Ebersold. “We think that the problem begins much earlier, with the in vitro tests that are performed at the starting point of translational nanomedicine: their static design is what often accounts for the discrepancies with the later in vivo tests.”

Explore further: Silver nanoparticles’ protein ‘corona’ affects their toxicity

More information: Debora Bonvin et al. Protein Corona: Impact of Lymph Versus Blood in a Complex In Vitro Environment, Small (2017). DOI: 10.1002/smll.201700409

A senior fellow at the Faculty of Chemistry, MSU, Vladimir Bochenkov, together with his colleagues from Denmark, have established the mechanism of interaction of silver nanoparticles with the cells of the immune system. The …

Hemostasis is a highly regulated process with key function for human life. The process is based on a rather complex interplay between endothelial cells, plasmatic coagulation and platelets. Deregulated hemostasis can result …

A Houston Methodist-led research team showed that the systemic administration of nanoparticles triggers an inflammatory response because of blood components accumulating on their surface. This finding may help researchers …

(Phys.org)One of the biggest challenges to realizing the potential of targeted therapies is keeping nanomaterials from accumulating in the liver or spleen. The liver and spleen are part of the mononuclear phagocyte system. …

Due to their nanoscale dimensions and sensitivity to light, quantum dots are being used for a number of bioimaging applications including in vivo imaging of tumor cells, detection of biomolecules, and measurement of pH changes.

Researchers at the National University of Singapore (NUS) have developed a technique to observe, in real time, how individual blood components interact and modify advanced nanoparticle therapeutics. The method, developed …

To understand the nature of something extremely complex, you often have to study its smallest parts. In trying to decipher the universe, for example, we search for gravitational waves or faint waves of light from the Big …

Researchers have studied how light can be used to observe the quantum nature of an electronic material. They captured light in graphene and slowed it down to the speed of the material’s electrons. Then electrons and light …

New research from the University of Liverpool, published in the journal Nanoscale, has probed the structure and material properties of protein machines in bacteria, which have the capacity to convert carbon dioxide into sugar …

When oil mixes with or enters into water, conventional methods of cleaning the water and removing the oil can be challenging, expensive and environmentally risky. But researchers in the Cockrell School of Engineering at The …

The endothelial cells that line blood vessels are packed tightly to keep blood inside and flowing, but scientists at Rice University and their colleagues have discovered it may be possible to selectively open gaps in those …

Recent research from the University of Nebraska-Lincoln may help future engineers of digital components get two (or more) for the space of one.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original:
A method to improve in vitro tests – Phys.Org

Read the Rest...

NanoViricides (NNVC) Says Topical Drug Candidates for Treatment of Shingles Demonstrated Excellent Inhibition of … – StreetInsider.com

§ June 7th, 2017 § Filed under Nano Medicine Comments Off on NanoViricides (NNVC) Says Topical Drug Candidates for Treatment of Shingles Demonstrated Excellent Inhibition of … – StreetInsider.com

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

NanoViricides, Inc., (NYSE: NNVC) (the “Company”), a pioneer in developing anti-viral nanomedicine drugs, reports that its topical drug candidates in development for the treatment of shingles have demonstrated excellent inhibition of the causative virus with practically no cytotoxicity in cell culture assays using multiple cell lines.

Two of the nanoviricide drug candidates in the HerpeCide program demonstrated almost complete inhibition of the varicella-zoster virus (VZV) at the highest drug doses, whereas acyclovir at the same drug dose exhibited partial inhibition of the virus. These comparative studies indicated that the antiviral effect of the herpecide drug candidates was almost five times superior to that of acyclovir. These studies were conducted using ARPE-19 cell line, which is a sensitive retinal cell line. Additional studies with another cell line, namely BS-C-1 produced comparable results. No cytotoxicity was observed at any of the doses tested for the herpecide drug candidates.

“We are excited with the excellent effectiveness and safety of these shingles antiviral drug candidates,” said Dr. Eugene Seymour, MD, MPH, CEO of the Company, adding, “We anticipate validation of our approach in skin culture studies as well. The human skin studies are already in progress in Professor Moffat’s Lab at the SUNY Syracuse Upstate Medical Center. Taken together, these results will put us on a quick path towards an IND filing.”

“We had strong confidence that the herpecide antivirals that we developed against HSV-1 would be effective against VZV as well. These studies validate our approach,” said Anil R. Diwan, PhD, President and Chairman of the Company, adding, “Importantly, the drug candidates that were successful against VZV are simpler to manufacture than our drug candidates that were previously found to be successful against HSV-1 in animal studies. We believe that this will reduce our workload towards an IND filing and help accelerate our progress to the clinic.”

Previously, the Company has demonstrated that treatment with certain herpecide drug candidates led to complete survival of small animals lethally infected with the aggressive and neurotropic HSV-1 strain H129c, wherein all of the untreated animals died. Those animal studies also reproducibly demonstrated dramatic improvements in clinical symptoms associated with herpes simplex virus infection, as illustrated by a complete absence of zosteriform spreading. Those animal studies were performed by TransPharm Preclinical Solutions (“TransPharm”), a pre-clinical services company in Jackson, MI, and by the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal then continued as a Professor Emeritus. Dr. Rosenthal is a leading researcher in herpes virus anti-viral agents and vaccines. He is now Professor of Biomedical Sciences, College of Medicine, at the Roseman University of Health Sciences, Summerlin Campus, Las Vegas, NV.

The Company thereafter expanded its HerpeCide program into development of topical treatments for (a) herpes labials (HSV-1), (b) genital herpes (HSV-2), (c) shingles (VZV), and (d) herpes keratitis. Of these, the shingles treatment program is currently the most advanced and is rapidly moving towards clinical candidate selection.

Continued here:
NanoViricides (NNVC) Says Topical Drug Candidates for Treatment of Shingles Demonstrated Excellent Inhibition of … – StreetInsider.com

Read the Rest...

Rallying Point – Harvard Medical School (registration)

§ June 2nd, 2017 § Filed under Nano Medicine Comments Off on Rallying Point – Harvard Medical School (registration)

Harvard Medical School researchers at Massachusetts General Hospital have identified a surprising new role for the immune cells called macrophages: improving the effectiveness ofnanoparticle-deliveredcancer therapies.

In theirScience Translational Medicinereport, the investigators describe finding how appropriately timed radiation therapy can improve the delivery of cancernanomedicinesas much as 600 percent by attracting macrophages to tumor blood vessels, which results in a transient burst of leakage from capillaries into the tumor.

Get more HMS news here.

The field ofnanomedicinehas worked to improve selective drug delivery to tumors for over a decade, typically by engineering ever more advancednanomaterialsand often with mixed clinical success, said first authorMiles Miller, HMS instructor in radiology at Mass General. Rather than focusing on thenanoparticlesthemselves, we used in vivo microscopy to discover how to rewire the structure of the tumor itself to more efficiently accumulate a variety ofnanomedicinesalready in clinical use.

Encapsulating cancer drugs innanoparticlescan improve how a drug is absorbed, distributed, metabolized and excreted by extending a drugs presence in the circulatory system and avoiding the toxic solvents used in infusion chemotherapy.

But in clinical practice, delivering nanoencapsulated drugs into patients tumors has been challenging, largely because of known factors in the microenvironment of the tumor. High pressures within tumors and low permeability of tumor blood vessels limit the passage of drugs into tumor cells.

A 2015 study by Miller and his colleagues showed that tumor-associated macrophages can improve delivery of nanoparticle-based therapies to tumor cells, and radiation therapy is known to increase the permeability of tumor vessels. But exactly how these effects are produced and how they could be combined to enhancenanomedicinedelivery was not known. Answering those questions was the goal of the current study.

Finding that this combination of radiation andnanomedicineleads to synergistic tumor eradication in mice provides motivation for clinical trials that combine tumor rewiring using radiation therapy withnanomedicine” – Miles Miller

Experiments in mouse models of cancer revealed that radiation therapy produced important changes in the tumor microenvironment, including greater blood vessel size and permeability and an increase in the number of macrophages relative to tumor cells. These changes did not appear until three to four days after administration of radiation therapy and disappeared by day 11.

Analysis of patient biopsy samples taken before and several days after radiation therapy for breast or cervical cancer revealed significant macrophage expansion in post-radiation samples, with the greatest increases in patients receiving the highest radiation dosage.

Additional mouse studies showed that, beginning three days after radiation therapy, the uptake ofnanoparticles, but not of solvent-delivered drugs, approximately doubled. High-resolution in vivo microscopy revealed that increases in vascular permeability occurred erratically with periods of low permeability interrupted by a bursting of vascular contents, includingnanoparticles, into the tumors.

The rate of bursting increased three days after radiation and was higher on larger blood vessels with adjacent macrophages. Removal of macrophages prevented the radiation-induced changes and the increased uptake ofnanoparticles.

Combining radiation therapy with cyclophosphamidea DNA-damaging drug that enhances nanoparticle delivery to tumor cells through similar tumor-priming mechanismsled to even greater nanoparticle uptake.

Testing the therapeutic effect of combining radiation therapy with a nanoparticle-encased chemotherapy drugs in a mouse model confirmed the efficacy of the strategy and the key role of macrophages.

While combining radiation with a solvent-based drug had no benefit compared with radiation alone, delivery of a nanoencapsulated version of the same drug three days after radiation therapy eliminated most tumors, an effect that was significantly reduced if macrophages were depleted.

Finding that this combination of radiation andnanomedicineleads to synergistic tumor eradication in mice provides motivation for clinical trials that combine tumor rewiring using radiation therapy withnanomedicine, Miller said.

Most of the treatments andnanomedicinesemployed in this study are FDA approved for cancer treatment, so this combination treatment strategy could be tested in clinical trials relatively quickly, he added. And given the role of macrophages in this approach, we are particularly interested in combining tumor irradiation andnanomedicinewith immuno-oncology therapies.

This study was supported by National Institutes of Health grants UO1CA206997, K99CA207744, R01EB010011 and P50GM107618.

Adapted from a Mass Generalnewsrelease.

Continue reading here:
Rallying Point – Harvard Medical School (registration)

Read the Rest...

Radiation Therapy, Macrophages Improve Efficacy Of Nanoparticle-Delivered Cancer Therapy – Photonics Online

§ June 2nd, 2017 § Filed under Nano Medicine Comments Off on Radiation Therapy, Macrophages Improve Efficacy Of Nanoparticle-Delivered Cancer Therapy – Photonics Online

A Massachusetts General Hospital (MGH) research team has identified a surprising new role for the immune cells called macrophages improving the effectiveness of nanoparticle-delivered cancer therapies. In theirScience Translational Medicinereport, the investigators describe finding how appropriately timed radiation therapy can improve the delivery of cancer nanomedicines as much as 600 percent by attracting macrophages to tumor blood vessels, which results in a transient burst of leakage from capillaries into the tumor.

The field of nanomedicine has worked to improve selective drug delivery to tumors for over a decade, typically by engineering ever more advanced nanomaterials and often with mixed clinical success, says lead author Miles Miller, PhD, of the MGHCenter for Systems Biology. Rather than focusing on the nanoparticles themselves, we used in vivo microscopy to discover how to rewire the structure of the tumor itself to more efficiently accumulate a variety of nanomedicines already in clinical use.

Encapsulating cancer drugs in nanoparticles can improve pharmacokinetics how a drug is absorbed, distributed, metabolized and excreted by extending a drugs presence in the circulation and avoiding the toxic solvents used in infusion chemotherapy. But in clinical practice, delivering nanoencapsulated drugs into patients tumors has been challenging, largely because of known factors in the microenvironment of the tumor. High pressures within tumors and low permeability of tumor blood vessels limit the passage of any drugs from the circulation into tumor cells.

A 2015 study by Miller and his colleagues showed that tumor-associated macrophages can improve delivery of nanoparticle-based therapies to tumor cells, and radiation therapy is known to increase the permeability of tumor vessels. But exactly how these effects are produced and how they could be combined to enhance nanomedicine delivery was not known. Answering those questions was the goal of the current study.

Experiments in mouse models of cancer revealed that radiation therapy produced important changes in the tumor microenvironment including greater blood vessel size and permeability and an increase in the number of macrophages relative to tumor cells. These changes did not appear until 3 to 4 days after administration of radiation therapy and disappeared by day 11. Analysis of patient biopsy samples taken before and several days after radiation therapy for breast or cervical cancer revealed significant macrophage expansion in post-radiation samples, with the greatest increases in patients receiving the highest radiation dosage.

Additional mouse studies showed that, beginning three days after radiation therapy, the uptake of nanoparticles but not of solvent-delivered drugs approximately doubled. High-resolution in vivo microscopy revealed that increases in vascular permeability occurred erratically, with periods of low permeability interrupted by a bursting of vascular contents, including nanoparticles, into the tumors. The rate of bursting increased three days after radiation and was higher on larger blood vessels with adjacent macrophages. Removal of macrophages prevented the radiation-induced changes and the increased uptake of nanoparticles. Combining radiation therapy with cyclophosphamide a DNA-damaging drug that enhances nanoparticle delivery to tumor cells through similar tumor-priming mechanisms led to even greater nanoparticle uptake.

Testing the therapeutic effect of combining radiation therapy with a nanoparticle-encased chemotherapy drugs in a mouse model confirmed the efficacy of the strategy and the key role of macrophages. While combining radiation with a solvent-based drug had no benefit compared with radiation alone, delivery of a nanoencapsulated version of the same drug three days after radiation therapy eliminated most tumors, an effect that was significantly reduced if macrophages were depleted.

Finding that this combination of radiation and nanomedicine leads to synergistic tumor eradication in mice provides motivation for clinical trials that combine tumor rewiring using radiation therapy with nanomedicine, says Miller, who is an instructor in Medicine at Harvard Medical School. Most of the treatments and nanomedicines employed in this study are FDA approved for cancer treatment, so this combination treatment strategy could be tested in clinical trials relatively quickly. And given the role of macrophages in this approach, we are particularly interested in combining tumor irradiation and nanomedicine with immuno-oncology therapies.

Ralph Weissleder, MD, PhD, director of the MGH Center for Systems Biology is senior author of the Science Translational Medicine paper. Additional co-authors are Ravi Chandra, MD, Michael Cuccarese, PhD, Christina Pfirschke, PhD, Camilla Engblom, PhD, Shawn Stapleton, PhD, Utsarga Adhikary, Rainer H. Kohler, PhD, James F. Mohan, PhD, and Mikael J. Pittet, PhD, all of the Center for Systems Biology. Support for the study includes National Institutes of Health grants UO1CA206997, K99CA207744, R01EB010011, and P50GM107618.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. TheMGH Research Instituteconducts the largest hospital-based research program in the nation, with an annual research budget of more than $800Mand major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of “Americas Best Hospitals.”

See the rest here:
Radiation Therapy, Macrophages Improve Efficacy Of Nanoparticle-Delivered Cancer Therapy – Photonics Online

Read the Rest...

« Older Entries Newer Entries »





Page 3«..2345..1020..»